Soc. Generale Call 650 Novo-Nordi.../ DE000SW3QL70 /
8/5/2024 9:32:46 AM | Chg.-0.81 | Bid10:00:35 PM | Ask10:00:35 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
2.60EUR | -23.75% | - Bid Size: - |
- Ask Size: - |
- | 650.00 DKK | 9/20/2024 | Call |
GlobeNewswire
6/28
SNIPR Biome receives funding for the development of CRISPR-medicines to improve Environmental Enteri...
GlobeNewswire
6/24
Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American ...
GlobeNewswire
6/18
Novo Nordisk announces presentation of data from key semaglutide clinical trials in diabetes, obesit...
GlobeNewswire
6/18
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for ...
GlobeNewswire
6/17
Veru Reminds Shareholders to Vote in Advance of Tomorrow’s Deadline for 2024 Annual Meeting of Share...
GlobeNewswire
6/13
Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Chil...
GlobeNewswire
6/11
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next...
GlobeNewswire
6/10
RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships
GlobeNewswire
5/31
Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia...
GlobeNewswire
5/30
Anaqua Annual User Experience Conference to Feature Keynotes from Microsoft, SAP, USPTO, and More
GlobeNewswire
5/15
Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Cl...
GlobeNewswire
5/14
Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Sci...